Austin, Texas, United States, June 9th, 2025, FinanceWire
- The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates.
- Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings.
- INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity.
- The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety.
- INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery.
Intelligent Bio Solutions INBS, a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies (https://ibn.fm/1JSTS).
The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
Contact
IBNwww.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.